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Preeclampsia is a maternal hypertensive disorder that affects up to 1 out of 12
pregnancies worldwide. It is characterized by proteinuria, endothelial dysfunction, and
elevated levels of the soluble form of the vascular endothelial growth factor receptor-1
(VEGFR-1, known as sFlt-1). sFlt-1 effects are mediated in part by decreasing VEGF
signaling. The direct effects of sFlt-1 on cellular metabolism and bioenergetics in
preeclampsia, have not been established. The goal of this study was to evaluate whether
sFlt-1 causes mitochondrial dysfunction leading to disruption of normal functioning in
endothelial and placental cells in preeclampsia. Endothelial cells (ECs) and first-trimester
trophoblast (HTR-8/SVneo) were treated with serum from preeclamptic women rich
in sFlt-1 or with the recombinant protein. sFlt-1, dose-dependently inhibited ECs
respiration and acidification rates indicating a metabolic phenotype switch enhancing
glycolytic flux. HTR-8/SVneo displayed a strong basal glycolytic metabolism, remaining
less sensitive to sFlt-1-induced mitochondrial impairment. Moreover, results obtained in
ECs exposed to serum from preeclamptic subjects demonstrated that increased sFlt-1
leads to metabolic perturbations accountable for mitochondrial dysfunction observed in
preeclampsia. sFlt-1 exacerbatedmitochondrial reactive oxygen species (ROS) formation
and mitochondrial membrane potential dissipation in ECs and trophoblasts exposed
to serum from preeclamptic women. Forcing oxidative metabolism by culturing cells
in galactose media, further sensitized cells to sFlt-1. This approach let us establish
that sFlt-1 targets mitochondrial function in ECs. Effects of sFlt-1 on HTR-8/SVneo
cells metabolism were amplified in galactose, demonstrating that sFlt-1 only target
cells that rely mainly on oxidative metabolism. Together, our results establish the early
metabolic perturbations induced by sFlt-1 and the resulting endothelial andmitochondrial
dysfunction in preeclampsia.
Keywords: preeclampsia, sFlt-1, mitochondrial dysfunction, endothelial dysfunction, oxidative stress and
metabolic perturbations, metabolism
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INTRODUCTION
Preeclampsia (PE) is an often-fatal cardiovascular complication
related to pregnancy, that affects almost 8% of all pregnancies
worldwide. Globally, it is associated with approximately 80,000
maternal and over 500,000 infant deaths annually, impacting
the lives of over 4 million women worldwide(Duley, 2009).
PE is characterized by maternal endothelial dysfunction
(ED) (Powe et al., 2011; Sánchez-Aranguren et al., 2014),
hypertension (LaMarca et al., 2008) and proteinuria (Maynard
and Karumanchi, 2011). Alterations in circulating anti-
angiogenic factors levels, such as the soluble form of the vascular
endothelial growth factor (VEGF) receptor-1 (sVEGF-R1),
commonly known as sFlt-1, have been associated to the onset of
PE (Maynard et al., 2003; Levine et al., 2004, 2006). Nonetheless,
the pathophysiology of PE remains unknown (Kanasaki and
Kalluri, 2009).
In normal pregnancies, uterine blood flow increases to
allow adequate perfusion of the placental intervillous space and
physiological oxidative stress (Chaiworapongsa et al., 2014).
In PE, a prolonged hypoxic placental microenvironment, due
to a reduction in placental perfusion and oxygen availability,
results in exacerbated oxidative stress (Chaiworapongsa et al.,
2014). Hypoxia triggers several cellular responses, including
increased placental angiogenesis (Zamudio, 2003), cell survival
and metabolic adaptations (Illsley et al., 1984), established in
developmental biology as “placental metabolic reprogramming”
(Illsley et al., 2010; Jose et al., 2011).
Mitochondrial activity is essential in pregnancy because
it sustains the metabolic activity of the placenta throughout
gestation (LaMarca et al., 2008). Recently, a potential association
between increased soluble anti-angiogenic factors levels and
mitochondrial dysfunction has been suggested (Jiang et al., 2015).
Exogenous administration of sFlt-1 in pregnant mice have shown
to induce placental mitochondrial swelling, oxidative stress
and apoptosis in trophoblasts (Jiang et al., 2015). In addition,
preeclamptic plasma mediators induced deleterious effects on
mitochondrial function of human umbilical vein endothelial
cells (HUVEC) (McCarthy and Kenny, 2016). Together, findings
suggest that mitochondrial function plays an important role in
the onset of PE. Nevertheless, the role of early dysregulated sFlt-1
levels in PE, to induce perturbations in the mitochondrial oxygen
consumption and bioenergetics in endothelium and placenta, has
not been established.
Here, we report the effects of PE serum on mitochondrial
oxygen consumption and metabolism in ECs and first-trimester
extravillous trophoblasts (HTR-8/SVneo). As early elevated
circulating levels of sFlt-1 are known to be implicated in the
development of the disease (Maynard et al., 2003; Levine et al.,
2004, 2006), we also established the effects of increasing levels
of exogenous sFlt-1 on mitochondrial function. We demonstrate
that PE serum significantly affects mitochondrial maximal
respiration and spare respiratory capacity of ECs and trophoblast,
enhancing a metabolic glycolytic phenotype. In addition, PE
serum-induced mitochondrial reactive oxygen species (mtROS)
formation. These effects were partially abrogated by exogenous
VEGF. Finally, sFlt-1 treatment caused a dose-dependent
loss of mitochondrial oxygen consumption in ECs and
trophoblasts, affecting mitochondrial maximal respirations and
spare respiratory capacities, and, inducing ametabolic phenotype
switch to glycolysis, only in ECs. Our results provide novel
insights on the differential metabolic perturbations exerted by
sFlt-1 in the endothelium and placenta and their overall role in
the development of PE.
MATERIALS AND METHODS
Subjects
Antecubital blood samples were collected from preeclamptic
(PE) (n = 23) and normotensive women (NOR) (n = 23),
before cesarean delivery. Subjects were recruited from the
Maternal Fetal Units of Fundación Cardiovascular de Colombia
(FCV), Floridablanca, Colombia and Clínica Materno Infantil
San Luis (CMISL), Bucaramanga, Colombia, using protocols
approved by hospital respective Ethics Committees. Ten
non-pregnant subjects were recruited as controls (CTL).
Preeclampsia diagnosis was established according to the
American College of Obstetricians and Gynecologists (American
College Obstetricians Gynecologist Task Force on Hypertension
in Pregnancy, 2013) criteria (Supplementary Table 1). Subjects
gave informed consent for their inclusion in the study.
Cell Culture
Bovine aortic endothelial cells (ECs) (passages 5–8) were
obtained from Cell Applications, Inc. (San Diego, CA, USA). ECs
were cultured in DMEM supplemented with 10% FBS (CellGro),
5.5mM glucose, 4mM L-glutamine, 1mM sodium pyruvate and
100 U/ml penicillin/streptomycin at 37◦C and 5% CO2. Prior to
experiments, ECs were cultured in DMEM containing 2% FBS
for 24 h. Extravillous trophoblast cells (HTR-8/SVneo, passages
75–82), are a well characterized, authenticated and immortalized
first-trimester extravillous trophoblast (EVT) cell line(Graham
et al., 1993). HTR-8/SVneo were cultured in RPMI-1640 (Gibco,
Grand Island, NY, USA) supplemented with 5% FBS and 100
U/ml penicillin/streptomycin at 37◦C and 5% CO2. To force
mitochondrial metabolism, ECs and HTR-8/SVneo cells were
grown in galactose supplemented media, matching the same
glucose concentrations used previously, for two passages prior
the analysis. Human recombinant sFlt-1 (VEGF-R1/Flt-1), and
VEGF were obtained from R&D Systems, (Minneapolis, MN,
USA). For in vitro correlation studies, cells were exposed to 2%
serum from recruited women (Rodgers et al., 1988; Maynard
et al., 2003).
Cell Viability Assays
MTT assay was performed as cell viability assays. Cells were
seeded at a density of 1 × 104 cells/well on 96-well plates
and cultured for 24 h. Then, cells were treated with 50 ng/mL
of sFlt-1 recombinant protein (Novoprotein Scientific, Summit,
NJ) for another 24 h. Cells were cultured in glucose and
galactose supplemented media. After treatments, cells were
exposed to 100 µL of MTT solution (5 mg/mL). Two hours
later, formazan crystals were solubilized in dimethyl sulfoxide
(DMSO). Absorbance was measured in a plate reader at 570 nm
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using a Varioskan Flash multimodal plate reader (Thermo Fisher
Scientific, Vantaa, Finland).
Mitochondrial Oxygen Consumption
Mitochondrial bioenergetics was assessed using an XFe24
Extracellular Flux Analyzer (Agilent Seahorse, Billerica,
MA, USA). ECs and HTR-8/SVneo were seeded in V7
Seahorse micro-well plates at 3.5–4.0 × 104 cells/well in
100 µL standard growth media. Cells were treated with
sFlt-1 recombinant protein (Novoprotein Scientific) and 2%
serum from recruited women, respectively, and incubated
at 37◦C and 5% CO2 for 24 h. Following treatments, culture
media was changed to a non-buffered DMEM media, to
allow temperature and pH equilibrium. Initially, oxygen
consumption rates (OCR) and extracellular acidification rates
(ECAR) were measured simultaneously three times to establish
a baseline rate. Then, to evaluate mitochondrial function,
oligomycin (1mM) (Sigma Aldrich), carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP) (0.5mM) (Sigma
Aldrich) and a mixture of rotenone and antimycin A (Rot/AntA)
(1mM) (Cayman Chemicals) were injected into each well
sequentially, with intervals of 3–5min of mixing between the
injections, to respectively inhibit the ATP synthase, uncouple
oxidative phosphorylation, and estimate non-mitochondrial
respiration. Cellular respiratory control ratio (RCR) was obtained
as the ratio of basal and oligomycin-inhibited (basal RCR) and
FCCP-stimulated and oligomycin-inhibited mitochondrial
respiratory rates (maximal RCR) (Brand and Nicholls, 2011;
Dranka et al., 2011). OCR and ECAR measurements were
normalized to protein content by the Bradford method
(Supplementary Methods and Supplementary Figure 1).
Aerobic Glycolysis
Treated cells were washed and subjected to glucose (5.5mM)
(Sigma Aldrich), oligomycin (1mM) (Sigma Aldrich) and 2-
deoxi-glucose (2-DG) (100mM) (Sigma Aldrich), subsequently,
to respectively induce glycolysis, inhibit ATP synthase and
estimate non-glycolytic acidification. Measurements were
normalized to protein content by the Bradford method
(Supplementary Methods and Supplementary Figure 1).
Mitochondrial ROS Formation
Mitochondrial ROS production (mtROS) was evaluated by
fluorescence microscopy, using the fluorescent probe MitoSOX
Red (Invitrogen, Oregon, USA). Briefly, ECs and trophoblast cells
were cultured in 24-well plates, exposed to serum from recruited
women and exogenous sFlt-1 (50 ng/mL), respectively, for 24 h.
Cells were washed twice with HBSS and incubated with 5µM
MitoSOX Red probe in HBSS for 15min at 37◦C in 5% CO2,
protected from light. Then, cells were washed again with HBSS
and the red fluorescence emitted at 580 nm was analyzed, using
a Nikon Eclipse Ti-S inverted microscope and NiS Elements
software.
Mitochondrial Membrane Potential
Changes in mitochondrial membrane potential (19m) were
performed using the JC-1 fluorescent dye by fluorescence
microscopy (Invitrogen, Oregon, USA). JC-1 accumulates within
the mitochondria and forms aggregates that emit red-orange
fluorescence (Ex: 550/Em: 600 nm). When the 9m is dissipated,
cells emit green fluorescence (Ex: 485/Em: 535 nm). Briefly,
ECs and HTR-8/SVneo cells were cultured in 24-well plates
at densities of 5.0 × 104 cells/well. Treatments with sFlt-1 or
serum were applied for 24 h. Then, cells were washed twice
with sterile Phosphate Buffered Saline (PBS) at 37◦C, followed
by incubation with 5µM of JC-1 in culture media for 30min
at 37◦C, protected from light. The red/green fluorescence was
evaluated using a Nikon Eclipse Ti-S inverted microscope and
NiS Elements software.
Statistical Analyses
Each test was performed in three independent experiments. Data
were plotted as means± SEM. Statistical analysis was performed
using Student T-test and ANOVA with Bonferroni’s post hoc test,
using Stata 8 statistical software (StataCorp, TX, USA). Values of
p < 0.05, p < 0.01, and p < 0.001 were considered statistically
significant.
RESULTS
In Vitro Correlation Model of PE: Role of
VEGF in Mitochondrial Bioenergetics
Early metabolic perturbations are considered the hallmark of
common human diseases (DeBerardinis and Thompson, 2012).
To understand the metabolic basis that would accompany
the onset of PE, we assessed the cellular bioenergetics profile
of ECs and HTR-8/SVneo cells, exposed to serum from
pregnant and not pregnant women. For these purposes, we
established a case-control study in where pregnant preeclamptic
(PE), normotensive (NOR), and non-pregnant women (CTL),
were recruited (Supplementary Table 1). Circulating sFlt-1
levels were determined in recruited women, to corroborate
preeclamptic conditions. As reported previously, sFlt-1 levels
were increased in PE women (Maynard et al., 2003; Levine
et al., 2004) by several orders of magnitude in comparison
with NOR and CTL patients (Supplementary Figure 2). Then,
serum from all groups was used to replace FBS at 2% in
culture media, to establish an in vitro correlation model (Rodgers
et al., 1988; Maynard et al., 2003) of PE. Next, the effects in
mitochondrial metabolism and bioenergetics were assessed, using
Agilent-Seahorse technology (Dranka et al., 2011) as described in
methods sections.
As evidenced in Figure 1A respiratory traces show that
treatment of ECs with serum from PE women induced a
profound change in mitochondrial respiration rates. Maximal
respiration and spare respiratory capacity rates were calculated
after FCCP administration. FCCP induces the collapse
of the mitochondrial membrane potential, leading to the
determination of maximum OCR (Brand and Nicholls, 2011;
Dranka et al., 2011). Administration of CTL and NOR serum
did not affect respiration rates (Figure 1A). As observed in
cell respiratory control ratios (RCR) (State 3/State 4), PE
serum significantly affected mitochondrial respiration profile,
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FIGURE 1 | Bioenergetics profile of cells treated with serum from PE women. ECs and HTR-8/SVneo cells were treated with 2% serum from NOR, CTL, and PE
women for 24 h. (A) Basal oxygen consumption rates (OCR), maximal respiration (OCR after FCCP administration) and spare respiratory capacity (Difference between
basal and maximal OCR), (B) Ratios of basal and maximal (Max) respiratory control (RCR) (State 3/state 4), (C) Energy phenotype map of basal and maximal OCR and
extracellular acidification rates (ECAR), measured in ECs. (D–F), are the same experiments as in (A–C), respectively, but evaluated in HTR-8/SVneo cells. Data are
presented as means ± SEM. (n = 5). In (A,D): *P < 0.05, **P < 0.01 vs. CTL, #P < 0.05, vs. NOR. In (B,E): *P < 0.05, vs. basal CTL RCR, #P < 0.05, vs. CTL
maximal RCR. ANOVA (Bonferroni’s post-hoc test).
suggesting mitochondrial dysfunction, associated with a low
substrate oxidation capacity (Figure 1B).
Interestingly, when we assessed the cell energy phenotype of
ECs, we found a slight increase in basal OCR in ECs treated
with NOR and PE serum. However, when cells were challenged
with FCCP to uncouple mitochondria, only CTL and NOR
treated cells showed an increase in both OCR and ECAR. ECs
treated with PE serum exhibited a drastic drop in OCR below
basal levels, with a non-significant increase in glycolytic function
(Figure 1C). This suggested that ECs under PE conditions
(modeled with serum from women with PE), are not going to
be able to cope with physiological challenges that will require an
increase in energy utilization via mitochondria.
To establish the effects of PE serum in placenta, we used
HTR-8/SVneo cells, which is an immortalized first trimester EVT
cell line, as our model. Since early perturbations of sFlt-1 will
be developing before the 20th-week of gestation, a trophoblast
cell line that resembles the metabolic profile from those early
stages was used. Results obtained after treatment with serum
from PE women showed a reduction in maximal respiration
in comparison with NOR and CTL serum of about 30%
(Figure 1D). As in ECs, PE serum depleted the spare respiratory
capacity rates. RCR determinations identified reduced oxidative
phosphorylation in NOR serum-treated trophoblasts, along
with an enhanced glycolytic response (Figure 1E). As observed
in ECs, PE serum induced a significant decrease in OCR
parameters, consistent with a weak coupling of respiration
for ATP synthesis and enhanced ability to activate glycolytic
pathways (Figures 1D–F).
Together, these results suggest that under full manifestation of
PE conditions, the combination of several PE-key players, along
with upregulated sFlt-1 (Maynard et al., 2003; Levine et al., 2004,
2006; Tosun et al., 2010; Vitoratos et al., 2010), will induce an
insightful effect in the energetic phenotype of both, ECs and
trophoblast, that will not allow them to metabolically respond to
harsh conditions.
Role of VEGF in Mitochondrial Function
in PE
Once the impact of PE serum was established in ECs and
trophoblasts, it was imperative to verify the implications of
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sFlt-1 in these observations. Although sFlt-1 levels in PE serum
were higher than in NOR and CTL, other factors like pro-
inflammatory molecules (i.e., TNF-α and IL-6), are known to be
present in serum as described extensively in the literature (Tosun
et al., 2010; Vitoratos et al., 2010), contributing with sFlt-1 to the
effects observed.
To address the role of sFlt-1 and VEGF bioavailabilities in
the early metabolic perturbations in PE, VEGF (20 ng/mL) was
administered to cells exposed to serum. VEGF administration
should discriminate the antagonizing effects of sFlt-1 in serum
from other possible factors. ECs and trophoblasts were treated
with serum alone, and serum containing VEGF. As shown in
(Figure 2A), VEGF administration to ECs treated with NOR
serum did not affect maximal respiration or spare respiratory
capacity. However, PE serum impaired the maximal respiration
and spare respiratory capacity of ECs (Figure 1A) and these
effects were partially reverted by VEGF (Figure 2A). This
suggests that reduced VEGF bioavailability, due to sFlt-1
up-regulation, affects mitochondrial function (Figures 2A,B).
VEGF co-treatment significantly improved maximal respiration
rates, resulting in increased RCR when compared to ECs treated
with PE serum (Figures 2A,B). Still, this improvement was not
enough to reach the levels detected in cells treated with NOR
serum. This scenario was similar in trophoblasts. PE serum
caused a significant decrease in the maximal respiration rate
and the addition of VEGF was not able to restore these values
(Figure 2C). Then, the dramatic decrease in the spare respiratory
capacity and RCR of cells treated with PE serum was partially
restored by VEGF (Figures 2C,D). These observations suggested
that sFlt-1 might be responsible for antagonizing the homeostatic
activity of VEGF, having a direct impact on mitochondrial
function and bioenergetics. However, it is expected that other
factors in PE serum (and to a lesser extent in NOR and CTL
women) are also contributing to the effects observed.
Next, we examined the effects on ECs and trophoblasts of
PE serum alone and with VEGF, in mitochondrial function, by
assessing the production of mtROS with Mito-SOX fluorescence
and 19m with JC-1 dye. In ECs, treatment with PE serum
caused a drastic increase in mtROS in comparison with CTL and
NOR serum. VEGF was only able to reduce mtROS generation
by approximately 30% in comparison with ECs treated with
PE serum (Figure 3A). In contrast, treatment in trophoblasts
caused a significant increase as compared to CTL serum of
33% with NOR serum treatment and 71% increase in mtROS
with PE serum (Figure 3B). VEGF decreased mtROS production
about 30%, as in trophoblasts treated with NOR serum. PE
FIGURE 2 | Role of VEGF in mitochondrial bioenergetics in preeclampsia. ECs and HTR-8/SVneo cells were treated with 2% serum from NOR, CTL, and PE women
with and without exogenous VEGF (20 ng/mL) for 24 h. (A) Maximal respiration (OCR after FCCP administration) and spare respiratory capacity (Difference between
basal and maximal OCR) in endothelial cells, (B) Basal and maximal (Max) RCR, (C,D) are the same experiments as in (A,B), respectively, but evaluated in
HTR-8/SVneo cells. Data are presented as means ± SEM. (n = 5). In (A,C): *P < 0.05, vs. NOR, #P < 0.05, vs. cells exposed to PE serum alone. In (B,D): *P <
0.05, vs. NOR maximal RCR, #P < 0.05, vs. PE maximal RCR. ANOVA (Bonferroni’s post hoc test).
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FIGURE 3 | VEGF restores mitochondrial function and abrogates ROS in preeclampsia. ECs and HTR-8/SVneo cells were treated with 2% serum from NOR, CTL,
and PE women with and without exogenous VEGF (20 ng/mL) for 24 h. (A) Mitochondrial ROS (mtROS) determinations by fluorescent microscopy using MitoSOX Red
fluorescent probe in ECs. (B) As in (A) but with trophoblasts cells. (C) PE serum dissipated the mitochondrial membrane potential (9m) measured by fluorescent
microscopy using JC-1 fluorescent dye in ECs and (D) trophoblasts. VEGF (20 ng/mL) restored the mitochondrial membrane potential to CTL levels in trophoblasts.
Scale: 100µm. Data are presented as means ± SEM. (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, vs. CTL exposed cells. #P < 0.05, vs. PE serum exposed cells,
ANOVA (Bonferroni’s post hoc test).
serum also caused changes in the 9m in both ECs and HTR-
8/SVneo cells. Treatment with PE serum caused a drop in 9m
of about 27% in comparison to ECs treated with CTL serum
(Figure 3C). Administration of VEGF was not able to restore
the 9m as evidenced in the 8% increase in 9m in treated ECs.
Similar results were obtained in treated trophoblasts (Figure 3D).
Cells treated with PE serum experienced a drop in 9m of
28% in comparison with CTL serum. Treatment with PE serum
and VEGF was only able to restore the drop in mitochondrial
membrane potential with a 7% increase. In contrast, the effects
of VEGF almost recover the changes in 9m to similar levels of
cells treated with NOR serum.
sFlt-1 Induces a Metabolic Phenotype
Switch to Glycolysis in ECs, but Not in
Trophoblasts
Circulating levels of sFlt-1 are known to increase drastically
prior the onset of clinical signs of PE (Maynard et al., 2003;
Levine et al., 2004, 2006). To assess the effects of sFlt-1 on
the mitochondrial bioenergetics of ECs and HTR-8/SVneo,
cells were treated with sFlt-1 (0–50 ng/mL) for 24 h and
subjected to OCR and ECAR measurements. As shown in
Figure 4A, sFlt-1 decreased basal and ATP-dependent OCR in
a dose-dependent manner in ECs. Also, significant changes
in FCCP-stimulated OCR were shown in sFlt-1-treated cells,
indicating that mitochondrial spare respiratory capacity was
also affected (Figure 4A). These evidence demonstrate that sFlt-
1-induced angiogenic imbalance, reduce the capacity of the
endothelium to respond to changes in energy demand coupled
to mitochondrial respiration (Supplementary Figure 3A). The
analysis of OCR versus ECAR in sFlt-1-treated ECs showed
an inhibition of the mitochondrial respiration, with a dose-
dependent ability to switch to glycolysis (Figure 4B). In addition,
the glycolytic response increased more than 5-fold in 50 ng/mL
sFlt-1-exposed cells, suggesting a metabolic phenotype switch
to glycolysis in ECs, after treatment with sFlt-1 (Figure 4C
and Supplementary Figure 3B). Regarding HTR-8/SVneo cells,
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FIGURE 4 | sFlt-1 induces a metabolic phenotype switch to glycolysis in ECs but not in trophoblasts. ECs and HTR-8/SVneo cells were exposed to 0, 10, 25, and
50 ng/mL of rh-sFlt-1 for 24 h. (A) Oxygen consumption rates (OCR), maximal respiration (OCR after FCCP administration) and spare respiratory capacity (Difference
between basal and maximal OCR), (B) Energetic phenotype map, basal and maximal OCR and extracellular acidification rates (ECAR), (C) ECAR determinations of
glycolysis rate and glycolytic reserve, evaluated in endothelial cells. (D-F), are the same experiments as in (A–C), respectively, but evaluated in HTR-8/SVneo cells.
Data is presented as means ± SEM. (n = 5), *P < 0.05, **P < 0.01, ***P < 0.001 vs. untreated controls, In (A,D): Student T-test. In (C,F): ANOVA (Bonferroni’s post
hoc test).
cells demonstrated a higher basal OCR with an overall reduced
FCCP-dependent OCR, in comparison to ECs, displaying high
glycolytic rates and glycolytic reserves even at basal conditions
(Figures 4E,F). Response to sFlt-1 treatment showed a reduction
in mitochondrial respiration without increases in the glycolytic
flux exerted by 50 ng/mL of sFlt-1 (Figures 4D–F).
Results obtained clearly state that in both, ECs and
HTR-8/SVneo, sFlt-1 is acting as a disruptor directly into
mitochondria. Nonetheless, based on the differential cell
energy phenotypes of ECs and HTR-8/SVneo, the effects are
interestingly dissimilar in both cell lines.
sFlt-1 Acts as a Mitochondrial
Bioenergetics Disruptor in ECs and
HTR-8/SVneo
To further confirm the effects of sFlt-1 as a mitochondrial
bioenergetics disruptor, mitochondrial metabolism (OXPHOS)
was forced by growing cells in galactose media (Robinson et al.,
1992; Marroquin et al., 2007). This approach forces cells to
exclusively rely on mitochondrial metabolism of glutamine for
their ATP energy requirements (Reitzer et al., 1979). Reliance on
OXPHOS for ATP production, sensitize cells to mitochondrial
disruptors(Marroquin et al., 2007; Dott et al., 2014).
ECs and HTR-8/SVneo exposed to galactose presented slower
growth rates in comparison to cells cultured in glucose media
(Figure 5A). ECs, cultured in galactose, did not evidence changes
in their viability or proliferations rates in comparison to cells
exposed to glucose (Figure 5B and Supplementary Figure 4A).
Nonetheless, when ECs were exposed to sFlt-1 in galactose
media, they had significant reduction in the proliferation rate
and viability of about 20% in comparison to non-treated cells
(Figure 5B and Supplementary Figure 4A).
Divergently, the culture of HTR-8/SVneo cells in galactose,
evidenced their dependence on glycolysis as a main source
of energy, as described previously (Figures 4E,F). By
forcing OXPHOS in HTR-8/SVneo cells, we confirmed
diminished proliferation and viability rates of about 50%
in comparison to cells grown in glucose (Figure 5C and
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Supplementary Figure 4B). These observations are consistent
with HTR-8/SVneo evolutionary metabolism of a first-trimester
trophoblast, previously defined to be contingent mainly on
non-oxidative pathways to support its energetic demands
(Illsley et al., 2010). Thus, treatment of HTR-8/SVneo
cells with sFlt-1 in galactose media evidenced a reduced
viability of about 40% in comparison to controls in galactose
(Figure 5C and Supplementary Figure 4B). Together, these
results evidenced that sFlt-1, as a mitochondrial disruptor, affects
more dramatically cells that rely on mitochondria machinery
for energy proposes, rather than those with a basal glycolytic
dependence for their metabolism.
To further corroborate the impact of sFlt-1 over the
mitochondrial function and ROS formation, we evaluated the
production of mtROS and 19m in ECs and trophoblasts, as
measured by fluorescence microscopy. As shown in Figure 6A,
using fluorescent probe MitoSOX Red, we evidenced that sFlt-
1 (50 ng/mL) significantly increased mtROS formation in ECs
1.5-fold, but these effects were not observed in trophoblasts
(Figure 6B). Then, the evaluation of the 19m using JC-
1 fluorescent dye, established that doses of 50 ng/mL of
exogenous sFlt-1, reduced 9m in ECs by 20% (Figure 6C).
Again, no significant changes were found in trophoblast cells
(Figure 6D). These results confirm our previous observations
FIGURE 5 | sFlt-1 acts as a mitochondrial bioenergetics disruptor in preeclampsia. (A) Morphological changes in endothelial cells (ECs) and trophoblasts cultured in
glucose and galactose media (40X). (B) Cell viability of ECs and (C) trophoblasts cultured in glucose and galactose media and exposed to exogenous 50 ng/mL of
sFlt-1 during 24 h. Scale: 100µm. Data are presented as means ± SEM. (n = 3), **P < 0.01, ***P < 0.001, vs. galactose exposed cells. #P < 0.05, vs.
glucose-exposed cells. Student T-test.
FIGURE 6 | sFlt-1 induces mitochondrial dysfunction in vitro. (A) Mitochondrial ROS (mtROS) determinations by fluorescent microscopy using MitoSOX Red
fluorescent probe demonstrate that sFlt-1 significantly induced mtROS formation in endothelial cells (ECs), while these effects were not observed in (B) trophoblasts.
(C) sFlt-1 dissipated the mitochondrial membrane potential (9m) measured by fluorescent microscopy using JC-1 fluorescent probe in ECs, but not in (D)
trophoblasts. Cells were exposed to sFlt-1 (50 ng/mL) for 24 h. Data is presented as means ± SEM. (n = 3), *P < 0.05 vs. untreated controls. Student T-test.
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regarding the role of sFlt-1 to induce alterations in mitochondrial
bioenergetics in ECs and its impact on the overall mitochondrial
function, as previously demonstrated in vivo (Jiang et al.,
2015).
DISCUSSION
PE remains as the leading cause of maternal and neonatal deaths
worldwide (Duley, 2009). Within the last decade, several reports
opened a novel window for understanding the pathogenesis of
the disease, by describing the role of circulating anti-angiogenic
factors like sFlt-1, in the development and early detection of
the disease (Maynard et al., 2003; Levine et al., 2004; Young
et al., 2010; Perni et al., 2012; Verlohren et al., 2012). sFlt-1
has been found to provoke endothelial dysfunction (Powe et al.,
2011; Sánchez-Aranguren et al., 2014), hypertension (LaMarca
et al., 2008) and proteinuria (Maynard and Karumanchi, 2011),
demonstrating its culprit role in the onset of PE (Roberts
and Rajakumar, 2009). The present study demonstrates the
striking effects of sFlt-1 and serum from PE women in the
overall cell energy metabolism, mitochondrial bioenergetics and
mitochondrial dysfunction, linked to oxidative stress in ECs
and first trimester EVT (HTR-8/SVneo cells). Early metabolic
perturbations are known to be the hallmark of a range of human
pathologies (DeBerardinis and Thompson, 2012). Then, the
study of cellular energy metabolism arrives a novel strategy for
understanding the etiology of diseases and potentially to develop
novel treatments targeting these alterations in energymetabolism
(Gohil et al., 2010).
sFlt-1, Increased in PE Serum, Induce
Metabolic Perturbations in Preeclampsia
By the aid of the Seahorse-Agilent Extracellular Flux Analyzer, we
evaluated the metabolic perturbations preceding the onset of PE.
In order to establish a model that resemble PE conditions, ECs
and HTR-8/Svneo cells were treated with serum from pregnant
women, normotensive and preeclamptic, based on current
diagnostic criteria (American College Obstetricians Gynecologist
Task Force on Hypertension in Pregnancy, 2013). ELISA analyses
showed increased sFlt-1 levels in serum from PE women by
several orders of magnitude, in comparison with NOR and CTL
serum levels, as reported previously (Maynard et al., 2003; Levine
et al., 2004, 2006).
In a normal pregnancy, circulating sFlt-1 levels increase with
gestation age (Maynard et al., 2005). However, in PE, due to
unknown mechanisms, sFlt-1 is dramatically upregulated (Fan
et al., 2014), resulting in increased circulating levels of sFlt-1 prior
the onset on the clinical signs of PE (Maynard et al., 2003; Levine
et al., 2004, 2006). Here, we have demonstrated and described the
alterations in the mitochondrial bioenergetics profiles induced
by sFlt-1 increased levels, in both cell lines tested. Our results
are in accordance with recent work showing that incubation of
HUVEC with 3% plasma from PE women, significantly reduced
the overall OCR, measured by a fluorescence-based approach,
when compared to cells treated with serum from uncomplicated
and non-pregnant women (McCarthy and Kenny, 2016). In
addition, our results demonstrate the culprit role of sFlt-1 in the
onset of metabolic alterations in PE. sFlt-1 might be responsible
for antagonizing the homeostatic activity of VEGF, having an
impact at the mitochondrial level. However, it is likely that other
molecules, existing in the maternal serum of PE women, could be
potentiating the effects observed.
We also showed that mtROS are increased in trophoblasts
exposed to NOR serum in comparison to cells exposed to CTL
serum. This fact is consistent with the increased oxidative stress
status at the intrauterine level, observed by others in normal
pregnancies (Chaiworapongsa et al., 2014). PE serum, in ECs and
trophoblasts, led to a significant increase in mtROS production
in comparison to cells exposed to NOR serum. The augmented
mitochondrial oxidative stress, evidenced an alteration in
mitochondrial function induced by elevated sFlt-1 levels, present
in PE serum. It is likely that increased mtROS production would
be directly related to the effects of sFlt-1 on mitochondrial
bioenergetics. As it has been reported previously in vivo, sFlt-
1 induces ROS formation in placental vessels and trophoblasts
(Jiang et al., 2015). Potential mechanisms of increased mtROS
formation have been associated to a reverse electron transport
through complex I, in the mitochondrial electron transport
chain, in response to an elevated NADH/NAD+ ratio (Murphy,
2009). Our observations suggest that dysregulated sFlt-1 levels
during pregnancy, induce metabolic perturbations and oxidative
stress that might contribute to vascular endothelial dysfunction
in PE.
sFlt-1 Induce a Metabolic Phenotype
Switch to Glycolysis in Endothelial Cells
To better understand the metabolic bases that would accompany
the onset of PE, we studied the role of increasing concentrations
of sFlt-1, as a potential early metabolic disturber. We showed a
dose-dependent loss of mitochondrial function in ECs treated
with sFlt-1. Treatment with increasing concentrations of sFlt-1,
evidenced a metabolic phenotype switch from OXPHOS to an
enhanced glycolytic cellular response, not been establish before.
Our data suggest that in PE, increasing sFlt-1 levels could result
in loss of mitochondrial function early in gestation, leading to
impaired bioenergetics profiles. Cell energy metabolism varies in
tissue of different origins (Benard et al., 2006). Therefore, cell
metabolism can be adapted according to the microenvironment
surrounding cells. In evidence, other authors have reported that
various growth conditions may alter metabolism, contributing
to a greater cell dependence on glycolysis (Jose et al., 2011).
Our observations of an enhanced glycolytic metabolism, along
with an impaired oxygen consumption, suggested a metabolic
reprogramming process, as described in tumor biology studies
(Jose et al., 2011). These observations illustrate how ECs
can alternate OXPHOS to glycolytic pathways under sFlt-1-
induced stressful conditions. Nonetheless, the potential effects
derived from the prolongation of a aerobic glycolytic metabolism
(Warburg effect) in ECs, remains to be determined. Enhanced
glycolysis linked to a reduced OXPHOS could markedly affect
ECs capabilities to switch from a quiescent metabolic state to an
energetic phenotype during angiogenesis.
Frontiers in Physiology | www.frontiersin.org 9 March 2018 | Volume 9 | Article 83
Sánchez-Aranguren et al. sFlt-1 Induces Metabolic Perturbations in Preeclampsia
Regarding HTR-8/SVneo cells, we found, as reported before
(Illsley et al., 2010), that they have a functional mitochondrial
machinery. In contrast to ECs, sFlt-1 treatment in trophoblasts,
causes a non-significant mild drop in OCR. Since the cell basal
energetic profile is glycolytic, the overall energetic phenotype
after sFlt-1 treatment was not impaired. Studies performed on
term isolated trophoblasts have shown that both, syncytium and
cytotrophoblast cells, exhibit high reserve respiratory capacity
(Maloyan et al., 2012) when compared with our results. This
suggests that trophoblast cells, in early stages of gestation, are
metabolically programmed to overlap and compensate for the
effects of metabolic disruptors. Based on these facts, we presumed
that in later stages of pregnancy, when placental function
reaches its inevitable end, the metabolic profile of trophoblasts
changes as their biological functions terminate. These suggest
that cells isolated from full-term placentas may not be the most
appropriate approach to study the effects of early metabolic
perturbations.
sFlt-1 Acts a Mitochondrial Disruptor
Our results demonstrate a dose-dependent alteration in the
mitochondrial bioenergetics, suggesting that sFlt-1 is acting as
mitochondrial disruptor. To demonstrate the ability of sFlt-1 to
act as a mitochondrial disruptor that drives energy metabolism
from OXPHOS to glycolysis, we forced ATP dependence on
OXPHOS, by culturing cells in galactose media. Since oxidation
of galactose to pyruvate through glycolysis yields no net
production of ATP, cells are more sensitive to mitochondrial
toxicants, than when grown in glucose (Marroquin et al., 2007).
First, culture of ECs in galactose did not involve changes in
proliferation rates or viabilities, consistent with their metabolic
flexibility to switch from ATP predominantly generated by
OXPHOS, to glycolysis as their main energy source (Vallerie and
Bornfeldt, 2015). sFlt-1 impaired ECs viability and proliferation
rates under OXPHOS dependence, demonstrating that cells that
rely mainly in mitochondrial metabolism are highly sensitive to
sFlt-1. Results were markedly drastic in trophoblasts. Galactose
media enhanced the effects of sFlt-1, decreasing cell viability and
proliferation rates of about 40%. In both cell lines tested, culture
in galactose media overblown sFlt-1 effects, demonstrating its
role as a mitochondrial disrupter, effects that are not basally
appreciated in glucose media. Previously, culture in galactose
has been employed to identify mitochondrial toxicants (Dott
et al., 2014) and molecules that target cellular metabolic
FIGURE 7 | Schematic view of the effects of sFlt-1 dysregulation over cellular metabolism and bioenergetics in PE. Dysregulated VEGF signaling due to up-regulation
of sFlt-1 levels in preeclampsia leads to reduced activation of VEGF receptors Flt-1 and Flk-1/KDR, respectively. Effects of dysregulated VEGF bioavailability affect
mitochondrial oxygen consumption (OCR), inducing a metabolic phenotype switch enhancing glycolytic response (ECAR) in endothelial cells, but not in trophoblasts.
sFlt-1 due to loss of mitochondrial bioenergetics increase oxidative stress in mitochondria (mtROS). Together, these events lead to mitochondrial dysfunction, that
would result in vascular dysfunction and the onset of preeclampsia.
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shifts as potential therapeutics for pathologies associated with
ischemia/reperfusion damage (Gohil et al., 2010).
The increased mtROS production and decreased
mitochondrial respiration, coupled with a higher glycolytic
capacity of ECs exposed to sFlt-1, evidenced oxidative stress and
a metabolic phenotype switch to compensate the detrimental
effects of sFlt-1 and mediators present in serum from PE women,
over the endothelium. Our results demonstrated that exogenous
sFlt-1 induce mtROS formation and a drop in the mitochondrial
membrane potential in ECs, but not in trophoblasts. This
suggested that sFlt-1 plays a key role in metabolic modulation
and reprogramming in endothelium during pregnancy.
Whereas, when sFlt-1 levels increase drastically, their role is
balanced toward an anti-angiogenic state that leads to metabolic
impairment, vascular dysfunction, and PE. sFlt-1 seems to be an
important linker between mitochondrial dysfunction, oxidative
stress and endothelial dysfunction (Figure 7).
Here we have demonstrated that in trophoblast and
endothelial cells, disruption of the finely-tuned VEGF signaling
by sFlt-1 affects mitochondrial function and metabolism in
preeclampsia. As Figure 7 reviews, sFlt-1 strongly impairs
mitochondrial metabolism and bioenergetics, increasing mROS
and inducing a metabolic switch to glycolysis in ECs. These
findings are very important because they confirm the differential
responses of sFlt-1 in both ECs and trophoblasts that are
directly related in the development of the disease, from the
maternal circulation and placenta, respectively. In addition,
results obtained in ECs have strong implications in the maternal
hypertension events that are the hallmark of PE. Various reports
have revealed the direct implication of VEGF signaling in the
regulation of mitochondrial function and angiogenesis (Wang
et al., 2011; Guo et al., 2017; Kim et al., 2017). However, the exact
mechanisms on how VEGF and downstream events regulate
mitochondrial function are still unknown. Nevertheless, the role
of the PI3k/Akt/mTOR pathways and eNOS and NO production
in relation to high levels of sFlt-1, VEGF signaling, and
mitochondrial function is currently under study. Establishing the
clear role of sFlt-1/VEGF signaling in PE is key for developing
novel strategies for preventing or treating this multifactorial
disease.
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Supplementary Figure 1 | Parameters of mitochondrial bioenergetics and
cellular metabolism in intact cells. (A) Oxygen consumption rates (OCR)
determinations and parameters of mitochondrial function. (B) Energetic
phenotype map shows the metabolic state of cells and (C) extracellular
acidification rates (ECAR) determination and parameters of the glycolytic
function.
Supplementary Figure 2 | sFlt-1 levels measured by ELISA. Serum levels were
measure in non-pregnant controls (CTL), normotensive (NOR) and preeclamptic
(PE) women by ELISA. Data is presented as means ± SEM. (n = 6), ∗P < 0.05 vs.
CTL, #P < 0.05 vs. NOR. ANOVA (Bonferroni’s post hoc test).
Supplementary Figure 3 | sFlt-1 induced mitochondrial bioenergetics
dysfunction in vitro. (A) Ratios of basal and maximal (Max) respiratory control
(RCR) (State 3/state 4) and (B) Extracellular acidification rates (ECAR) yield by
time, demonstrate a metabolic phenotype switch from mitochondrial
phosphorylation to glycolysis, in endothelial cells exposed to 0, 10, 25, and
50 ng/mL of exogenous sFlt-1 for 24 h. Data is presented as means ± SEM
(n = 5), ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. maximal RCR measured in
untreated controls. ANOVA (Bonferroni’s post-hoc test).
Supplementary Figure 4 | sFlt-1 acts as a mitochondrial bioenergetics disruptor.
(A) Cell proliferation counts measured in endothelial cells and (B) trophoblasts
cultured in glucose and galactose media and also exposed to 50 ng/mL of
exogenous sFlt-1 for 24, 48, and 72 h. Data is presented as means ± SEM.
(n = 3), ∗P < 0.05, vs. galactose exposed cells. #P < 0.05, vs. glucose exposed
cells. ANOVA (Bonferroni’s post-hoc test).
Supplementary Table 1 | Clinical characteristics of the recruited women. Data is
presented as means ± SEM. Primiparous variable values are presented in %.
∗P = <0.05, vs. non pregnant controls (CTL), #P < 0.01 vs. NOR group. N.A.
Data not available.
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